Search

Displaying results 9401 - 9410 of 10000 in total
  1. Drug

    DA-8031

    go.drugbank.com/drugs/DB19024
    Investigational

    DA-8031 is under investigation in clinical trial NCT01798667 (Clinical Trial to Evaluate the Efficacy and Safety of DA-8031 in Male Patients With Premature Ejaculation).

  2. Drug

    Inupadenant

    go.drugbank.com/drugs/DB19129
    Investigational

    Inupadenant is under investigation in clinical trial NCT05060432 (Study of EOS-448 With Standard of Care And/or Investigational Therapies in Participants With Advanced Solid Tumors).

  3. Drug

    Remlarsen

    go.drugbank.com/drugs/DB19131
    Investigational

    Remlarsen is under investigation in clinical trial NCT03601052 (Efficacy, Safety, and Tolerability of Remlarsen (MRG-201) Following Intradermal Injection in Subjects With a History of Keloids).

  4. Drug

    PF-07038124

    go.drugbank.com/drugs/DB19143
    Investigational

    PF-07038124 is under investigation in clinical trial NCT05298033 (Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo).

  5. Drug

    Tigozertinib

    go.drugbank.com/drugs/DB19239
    Investigational

    Tigozertinib (BLU-945) is currently under investigation in clinical trial NCT04862780 (Phase 1/​2 Study Targeting EGFR Resistance Mechanisms in NSCLC) for the treatment of NSCLC.

  6. Drug

    Sabirnetug

    go.drugbank.com/drugs/DB19438
    Investigational

    Sabirnetug is under investigation in clinical trial NCT06335173 (A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)).

  7. Drug

    CTA30X UCAR-T

    go.drugbank.com/drugs/DB24819
    Investigational

    CTA30X UCAR-T is a biologic drug. CTA30X UCAR-T is under investigation in clinical trial NCT05015972 (UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies).

  8. Drug

    Glufosfamide

    go.drugbank.com/drugs/DB06177
    Investigational

  9. Drug

    Darinaparsin

    go.drugbank.com/drugs/DB06179
    Investigational

  10. Drug

    Oxyphenbutazone

    go.drugbank.com/drugs/DB03585
    ApprovedWithdrawn

    Oxyphenbutazone was withdrawn from the Canadian market in March 1985 due to concerns regarding bone marrow suppression.